• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Tivic Health Systems Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8/13/24 4:28:04 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $TIVC alert in real time by email
    8-K
    0001787740false00017877402024-08-092024-08-09

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 09, 2024

     

     

    Tivic Health Systems, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-41052

    81-4016391

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    47685 Lakeview Blvd.

     

    Fremont, California

     

    94538

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 888 276-6888

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    TIVC

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On August 9, 2024, the Company adopted its Amended and Restated 2021 Equity Incentive Plan (the “A&R Plan”), which amends and restates the Company’s 2021 Equity Incentive Plan (the “Original Plan”) in full. The Company’s Board of Directors (the “Board”) unanimously approved the adoption of the A&R Plan, subject to stockholder approval, on June 15, 2024, and, as described in Item 5.07 below, the Company’s stockholders approved the A&R Plan at the Company’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”) held on August 9, 2024.

    The A&R Plan amends the Original Plan to:

    •
    increase the number of shares of common stock authorized for issuance thereunder from 92,376 shares to 1,000,000 shares;
    •
    remove the limitation on the number of Award Shares that may be issued pursuant to the exercise of incentive stock options issued thereunder;
    •
    remove language specifying how Award Shares will be counted for purposes of determining the number of Award Shares available for the grant of Stock Awards thereunder;
    •
    remove the limitations on granting awards with vesting less than twelve months from the date of grant; and
    •
    remove the limitation on the aggregate value of all compensation that may be granted or paid to any individual for service as a non-employee director of the Company in any given calendar year.

    Additional information regarding the A&R Plan is set forth in the Company’s Definitive Proxy Statement on Schedule 14A (the “Proxy Statement”) filed by the Company with the Securities and Exchange Commission on June 28, 2024, which information is incorporated herein by reference. Such information and the foregoing description of the A&R Plan do not purport to be complete and are qualified in their entirety by reference to the full text of the Company’s A&R Plan, a copy of which is attached to this Current Report on Form 8-K (“Current Report”) as Exhibit 10.1 and is incorporated herein by reference.

    Item 5.07 Submission of Matters to a Vote of Security Holders.

    On August 9, 2024, the Company held the Annual Meeting in a virtual format. At the close of business on June 17, 2024, the record date for the Annual Meeting, there were 6,183,592 shares of Company common stock issued and outstanding, which constituted all of the issued and outstanding capital stock of the Company as of the record date. At the Annual Meeting, 2,395,964 of the Company’s 6,183,592 shares of common stock entitled to vote as of the record date, or approximately 38.7%, were represented by proxy or in person (virtually), and, therefore, a quorum was present.

    The proposals voted on at the Annual Meeting are more fully described in the Proxy Statement, which information is incorporated herein by reference.

    The final voting results on the proposals presented for stockholder approval at the Annual Meeting were as follows:

    Proposal No. 1: The Company’s stockholders elected two Class III directors, to hold office until the Company’s 2027 annual meeting of stockholders, or until their successors are duly elected and qualified, subject to prior death, resignation or removal, as follows:

    Name of Director

    Votes For

    Withhold

    Broker Non-Votes

    Jennifer Ernst

    654,527

    149,582

    1,591,855

    Sheryle Bolton

    596,810

    207,299

    1,591,855

    Proposal No. 2: The Company’s stockholders approved the adoption of the A&R Plan, as follows:

     

    Votes For

    Votes Against

    Abstentions

    Broker Non-Votes

    581,820

    215,605

    6,684

    1,591,855

    Proposal No. 3: The Company’s stockholders ratified the selection of Rosenberg Rich Baker Berman, P.A. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024, as follows:

     

    Votes For

    Votes Against

    Abstentions

    Broker Non-Votes

       2,241,997

    153,663

    304

    -

     


    Proposal No. 4: The Company’s stockholders approved the adjournment of the Annual Meeting to another place, or a later date or dates, if necessary or appropriate, to solicit additional proxies in favor of the proposals listed above at the time of the Annual Meeting, as follows:

     

    Votes For

    Votes Against

    Abstentions

    Broker Non-Votes

    1,993,342

    390,670

    11,952

    -

     

    Although Proposal No. 4 was approved by the Company’s stockholders, the chair of the Annual Meeting did not elect to adjourn the meeting, as all of the foregoing proposals were also approved.

    Item 9.01 Financial Statements and Exhibits.

     

    (d)

    Exhibits

    Exhibit No.

    Description

    10.1

    Tivic Health System, Inc. Amended and Restated 2021 Equity Incentive Plan, dated August 9, 2024.

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    TIVIC HEALTH SYSTEMS, INC.

     

     

     

     

    Date:

    August 13, 2024

    By:

    /s/ Jennifer Ernst

     

     

     

    Name: Jennifer Ernst
    Title: Chief Executive Officer

     


    Get the next $TIVC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TIVC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TIVC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Valauri Christina Rizopoulos

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    4/2/26 9:49:13 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Wolf Lisa G

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    3/19/26 9:14:41 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Operating Officer Handley Michael K converted options into 8,824 shares (SEC Form 4)

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    2/20/26 4:19:42 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $TIVC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Presenting on Emerging Growth Conference 91 Day 2 on April 2; Register to live stream

    MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting TodayWednesday, April 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you a

    4/1/26 7:00:00 AM ET
    $AEMD
    $ATCH
    $BESS
    Medical/Dental Instruments
    Health Care
    Finance: Consumer Services
    Finance

    Presenting on Emerging Growth Conference 91 Day 1 on April 1; Register to live stream

    MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - WednesdayApril 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to

    3/31/26 7:00:00 AM ET
    $AEMD
    $ATCH
    $BESS
    Medical/Dental Instruments
    Health Care
    Finance: Consumer Services
    Finance

    Presenting on Emerging Growth Conference 89 Day 2 on January 22; Register to live stream

    MIAMI, Jan. 21, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of Day 2 of the 89th Emerging Growth Conference on January 21 & 22, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - Presenting Today - January 21, 2026 8:45Virtual Lobby opens.Register for the Conference. If you alread

    1/21/26 7:00:00 AM ET
    $CLNN
    $DEVS
    $DGXX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance/Investors Services
    Finance

    $TIVC
    SEC Filings

    View All

    SEC Form 10-K filed by Tivic Health Systems Inc.

    10-K - Tivic Health Systems, Inc. (0001787740) (Filer)

    3/30/26 5:34:51 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tivic Health Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

    3/25/26 4:25:57 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tivic Health Systems Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

    3/20/26 5:15:08 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $TIVC
    Leadership Updates

    Live Leadership Updates

    View All

    Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine. When: Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT Panel Title: Building a Big Tent Bioelectronic Medicine stands to disrupt how we diagnose, treat, and manage disease, but fulfilling that promise requires broad alignment across the healthcare ecosystem. This session will explore how to rally the global community,

    10/22/25 2:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team

    Handley Joins as President of Tivic Biopharma and Chief Operating Officer of Tivic Health Following Its Licensing of Strategic Biopharma Assets From Statera Biopharma Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma, Inc., has joined Tivic Health as the President of Tivic Biopharma, a newly formed division of Tivic Health. Additionally, he will assume the role of Chief Operating Officer of Tivic Health and will work closely with the CEO and other leadership team members to develop and operationalize company-wide strategies. His key responsi

    2/24/25 8:15:00 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tivic Health Appoints Lisa Wolf as Interim Chief Financial Officer

    Kimberly Bambach, Ms. Wolf's predecessor, continues with Tivic as advisor focused on strategic transactions and special projects Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to announce the appointment of Lisa Wolf as Interim Chief Financial Officer (CFO) of the company, effective October 1, 2024. Ms. Wolf will take over from Kimberly Bambach, who has served as the company's interim CFO since April 2023. Ms. Bambach will continue with Tivic in an advisory role for strategic transactions and other special projects. "Lisa has served as a senior member of Tivic's finance team for over two

    9/13/24 5:29:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $TIVC
    Financials

    Live finance-specific insights

    View All

    Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that it will report its third quarter results for 2025 via pre-recorded conference call and webcast on Friday, November 14, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 230582 Webcast Link https://www.webcaster5.com/Webcast/Page/2865/53145 About Tivic Health Systems, Inc. Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell

    11/6/25 9:30:00 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tivic Reports Second Quarter 2025 Financial Results

    Company advances its TLR5 agonist program and prepares to report VNS clinical data Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced financial results for the second quarter and six months ended June 30, 2025. "We have established a strong foundation for Tivic's strategic transformation with our expansion into biopharmaceuticals, making us unique in treating disease by addressing both the body's biochemical and bioelectronic systems," stated Tivic CEO Jennifer Ernst. "To maximize our focus on the compelling, late-stage clinical pipeline, we have increasingly shifted resources away from consumer healthtech and are now planning to exit

    8/14/25 4:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tivic Health to Report Second Quarter 2025 Financial Results on August 14th Via Conference Call and Webcast

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today announced that it will report its second quarter results for 2025 via pre-recorded conference call and webcast on Thursday, August 14, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 793820 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/52776 About Tivic Health Systems, Inc. Tivic Health seeks to treat underserved medical conditions through biochemical and bioelectric therapies that modulate patients' immune system. The company's

    8/7/25 8:30:00 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $TIVC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tivic Health Systems Inc.

    SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

    5/15/24 4:47:23 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Tivic Health Systems Inc. (Amendment)

    SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

    2/9/24 4:05:08 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Tivic Health Systems Inc. (Amendment)

    SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

    2/1/24 9:01:29 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care